Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanjing Delova
Nanjing, Jiangsu, Chinadelovabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nanjing Delova is a clinical-stage biotechnology company based in China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages a proprietary structure-based drug design (SBDD) platform to target high-value oncogenic drivers and immunological pathways. Its pipeline includes several potent inhibitors targeting FGFR, RET, and BTK, with lead programs currently undergoing clinical evaluation for various solid tumors and hematological malignancies. Delova aims to address unmet medical needs through precision medicine and has secured significant backing from prominent venture capital firms including Lilly Asia Ventures and Qiming Venture Partners.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Nanjing Delova.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Delova.